Our analysis indicates there is over 50% upside to the share price from current levels (with some not-too-unreasonable DCF scenarios indicating as much as 100% upside), although it would likely take several years to close this gap to intrinsic value.
Sanofi Is the Best Value in the Big Pharma Space
Published: July 03, 2012